Oral News and Research

RSS

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

Today, during the 39th Annual Meeting of the American Association for Dental Research, convening at the Walter E. Washington Convention Center in Washington, DC, lead researcher M. Tong, The Ohio State University, will present a poster of a study titled "Epithelial-to-Endothelial Transition: An Epithelial Phenotypic Modulation Facilitating Oral-Squamous-Cell Carcinoma Progression."

5 Mar 2010

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Shire plc, the global specialty biopharmaceutical company, announces that the United States District Court for the District of Columbia ("Court"), following extensive briefing by the parties and an oral hearing, has upheld the decision of the U.S. Food and Drug Administration ("FDA") to grant 5-year New Chemical Entity ("NCE") exclusivity to lisdexamfetamine dimesylate-currently marketed by Shire U.S. Inc. for the treatment of attention-deficit hyperactivity disorder under the name VYVANSE(R).

5 Mar 2010

Proper diagnosis, treatment and good skin care help control acne and rosacea

Acne and rosacea are two seemingly different skin conditions that have one important thing in common: both are chronic and extremely common skin conditions. However, dermatologists recommend that with proper diagnosis, treatment and a healthy dose of good, old-fashioned skin care, acne and rosacea can be less of a nuisance for patients.

5 Mar 2010

Dermatologist addresses common parasitic infestations and latest treatment options at Academy Annual Meeting

If simply the thought of bedbugs, scabies and head lice makes you feel a little itchy, imagine how those affected by these common infestations feel when they learn what has been creeping around them and causing symptoms such as intense itching, red bite marks or irritated scalps.

5 Mar 2010

Vaxart raises $12.5M to advance Phase I clinical trials on Avian flu vaccine

Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has closed a $12.5 million Series B financing, led by Care Capital of Princeton NJ. The funding will be used to advance the Company's lead product, an oral vaccine for Avian influenza, through Phase I clinical trials.

4 Mar 2010

Dermatologist speaks about common forms of hair loss and treatment options at 68th Annual Meeting

For many women, unexplained hair loss can take a significant psychological toll on their overall quality of life. From altering their hairstyle to hide a thinning part to scaling back their hair care regimen in an effort to halt further hair loss, women try countless ways to cover up this problem - and the results are often lukewarm at best.

4 Mar 2010

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

NeoStem, Inc., an international biopharmaceutical company with operations in the U.S. and China, announced today that it has entered into a sponsored research agreement (SRA) with the University of Michigan to evaluate bone defect repairs using human stem cells. The one-year project, beginning in March, will be funded through the proceeds of a $108,746 grant from the National Institutes of Health (NIH) under the Small Business Innovative Research Program (SBIR).

4 Mar 2010

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Watson Pharmaceuticals, Inc. today announced an agreement to expand their Women's Health brand product portfolio with the acquisition of the exclusive U.S. rights to Columbia Laboratories, Inc.'s bioadhesive progesterone gel products currently marketed under the trade names CRINONE® and PROCHIEVE® for the indications of infertility and secondary amenorrhea.

4 Mar 2010

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Scientists are beginning to find out why people with Parkinson's disease often feel socially awkward. Parkinson's patients find it harder to recognize expressions of emotion in other people's faces and voices, report two studies published by the American Psychological Association.

4 Mar 2010

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

Atacama Labs Oy has developed an innovative oral drug delivery technology (called 'pneumatic dry granulation' or 'PDG Technology(TM)'). The technology is aimed to replace existing solid dosage form development and manufacturing methods (like wet granulation or standard roller compaction) and will help both NCE galenic developers and life cycle managers to overcome development or differentiation issues.

4 Mar 2010

Low-income children and adults at several California sites to receive free dental care

Nearly 28 percent of California's children have untreated tooth decay, according to the 2006 California Smile Survey, Mommy It Hurts to Chew. Families with low incomes and people with complex medical conditions face considerable barriers to obtaining dental care and have significantly worse oral health than other segments of the population.

4 Mar 2010

Study: 73% of disadvantaged kids in Los Angeles County have untreated caries

A huge percentage of underprivileged kids in Los Angeles County have infectious dental disease that's gone unchecked, according to a study led by the Herman Ostrow School of Dentistry of the University of Southern California.

4 Mar 2010

Also in Global Health News: U.S. Ambassador to U.N.; Male circumcision; River blindness in Ecuador; Nursing shortage in Caribbean; Maternal health in Bolivia; Drug-resistant TB in North Korea; Cholera vaccine

Betty King reported to her new position as U.S. ambassador to the U.N. in Geneva on Wednesday, the Associated Press reports. "Washington's Geneva mission had been without an ambassador since Warren W. Tichenor left his post on Jan. 20, 2009 - when Barack Obama was sworn in as president," according to the news service (3/3).

4 Mar 2010

Elsevier releases special issue to mark the 25th anniversary of antiretroviral drug development

Elsevier, the world-leading publisher of scientific, technical and medical information products and services, released a special issue of the journal Antiviral Research (www.sciencedirect.com/science/journal/01663542), marking the 25th anniversary of antiretroviral drug development.

4 Mar 2010

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Anavex Life Sciences Corp. today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

4 Mar 2010

Covidien: Mallinckrodt launches Oral Transmucosal Fentanyl Citrate

Covidien, a leading global provider of healthcare products, today announced that Mallinckrodt Inc., a Covidien company, has launched its Oral Transmucosal Fentanyl Citrate (CII) to distributors serving retail pharmacies across the country.

3 Mar 2010

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

YM BioSciences Inc., announces that it filed a Form 6K describing that certain US patents for nimotuzumab licensed to YM's majority-owned Canadian subsidiary , CIMYM BioSciences Inc., have become subject to a lien in the United States, pursuant to a court order, to a third party.

3 Mar 2010

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced initial, positive results from a clinical trial evaluating 12 months of treatment with the EndoBarrier™ Gastrointestinal Liner.

3 Mar 2010

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

Data from two Phase III studies of Merck’s investigational fixed-dose combinations of mometasone furoate and formoterol fumarate (MF/F) were presented by researchers today in two poster presentations at the American Academy of Allergy, Asthma & Immunology (AAAAI) annual meeting.

3 Mar 2010

New dental device takes fear and pain out of anesthetic injections

DentalVibe™ a new dental device now on the market takes the fear and pain out of dental injections. The product design firm, Bresslergroup, teamed with Dr. Steven G. Goldberg, DDS, to design the easy to use tool. Research shows that fear of a painful anesthetic injection keeps 50% of the patient population away from the dentist.

3 Mar 2010

Oral News and Research

OSCC cells express VEGFR1, VEGFR2 and serve as targets and effectors for VEGF: Study

FDA's 5-year NCE exclusivity grant to VYVANSE: Court upholds decision

Proper diagnosis, treatment and good skin care help control acne and rosacea

Dermatologist addresses common parasitic infestations and latest treatment options at Academy Annual Meeting

Vaxart raises $12.5M to advance Phase I clinical trials on Avian flu vaccine

Dermatologist speaks about common forms of hair loss and treatment options at 68th Annual Meeting

Evaluating bone defect repairs using human stem cells: NeoStem, University of Michigan enter into SRA

Watson Pharmaceuticals to acquire U.S. rights to Columbia's bioadhesive progesterone gel products

Parkinson's patients find facial and vocal expression difficult to read; deep brain stimulation seems to make it worse

Atacama Labs and Excella partner to sell PDG Granule and Tablet Manufacturing Services

Low-income children and adults at several California sites to receive free dental care

Study: 73% of disadvantaged kids in Los Angeles County have untreated caries

Also in Global Health News: U.S. Ambassador to U.N.; Male circumcision; River blindness in Ecuador; Nursing shortage in Caribbean; Maternal health in Bolivia; Drug-resistant TB in North Korea; Cholera vaccine

Elsevier releases special issue to mark the 25th anniversary of antiretroviral drug development

Failure of Alzheimer's drug Dimebon: Anavex Life Sciences comments

Covidien: Mallinckrodt launches Oral Transmucosal Fentanyl Citrate

YM BioSciences files Form 6K regarding certain nimotuzumab US patents

Positive clinical trial results of EndoBarrier Gastrointestinal Liner device announced

Merck’s MF/F Phase III study data presented at AAAAI annual meeting

New dental device takes fear and pain out of anesthetic injections

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News